Mitsubishi Tanabe hit by more recall woes
This article was originally published in Scrip
Japan's Mitsubishi Tanabe Pharma (MTP) has been hit again by concerns over its quality assurance procedures after it admitted that certain required tests were not performed on some lots of injected products before their release into the market.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.